Therapeutic drug monitoring of mycophenolic acid: A potential treatment for lupus nephritis

Kidney International

Volumn 78, Issue 4, 2010, Pages 335-336

  Pawinski, Tomasz ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; MYCOPHENOLIC ACID;

AREA UNDER THE CURVE; CLINICAL PRACTICE; DRUG MONITORING; ENTERIC COATED TABLET; GRAFT REJECTION; HUMAN; LUPUS ERYTHEMATOSUS NEPHRITIS; NOTE; PRIORITY JOURNAL;

EID: 77955134607     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2010.181     Document Type: Note

References (6)

1. Lertdumrongluk P, Somparn P, Kittanamongkolchai W et al. Pharmacokinetics of mycophenolic acid in severe lupus nephritis. Kidney Int 2010; 78: 389-395.
2. Ginzler EM, Dooley MA, Aranow C et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl Med 2005; 353: 2219-2228.
3. Shaw LM, Nicholls A, Hale M et al. Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion. Ther Drug Monit 2001; 23: 305-315.
4. Shaw LM, Koreck a M, Venkataraman R et al. Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies. Am J Transplant 2003; 3: 534-542.
5. De Winter BC, van Gelder T, Glander P et al. Population pharmacokinetics of mycophenolic acid: a comparison between enteric-coated mycophenolate sodium and nycophenolate mofetil in renal transplant recipients. Clin Pharmacokinet 2008; 47: 827-838.
6. Cattaneo D, Cortinovis N, Baldelli S et al. Pharmacokinetics of mycophenolate sodium and comparison with the mofetil formulation in stable kidney transplant recipients. Clin J Am Soc Nephrol 2007; 2: 1147-1155.